Cannabinol (CBN) is a mildly psychoactive phytocannabinoid that acts as a low affinity partial agonist at both CB1 and CB2 receptors. This activity at CB1 and CB2 receptors constitutes interaction of CBN with the endocannabinoid system (ECS). Although CBN shares the same mechanism of action as other phytocannabinoids (e.g., Delta-9-tetrahydrocannabinol, Δ9-THC), it has a lower affinity for CB1 receptors, meaning that much higher doses of CBN are required in order to experience effects, such as mild sedation. It was the first cannabinoid to be isolated from cannabis and was discovered in 1896. Antimicrobial and anti-inflammatory / immunosuppressive effects[15] Potential efficacy in treatment of ocular disease and epidermolysis bullosa[15] Reported neuroprotective effects (synergistic if coadministered with other cannabinoids)[15] Relevance to pain, itch, and inflammation via TRP channel activity[15]
